Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 5, 2014
Janus-faces of NME-oncoprotein interactionsNikolina Vlatković, Shie-Hong Chang, Mark T BoydCellular and Molecular Life Sciences : CMLS|May 21, 2013
Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapyNikolina Vlatković, Mark T Boyd, Carlos P RubbiCurrent Pharmaceutical Design|March 12, 2011
Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit allNikolina Vlatković, Kerryanne Crawford, Carlos P Rubbi, et al.Cancer Research|August 3, 2005
p53 regulation and function in renal cell carcinomaHazel E Warburton, Mark Brady, Nikolina Vlatković, et al.Cancer|January 7, 2010
p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?Aidan P Noon, Nikolina Vlatković, Radosław Polański, et al.Plos One|January 19, 2012
Postnatal changes in the expression pattern of the imprinted signalling protein XLαs underlie the changing phenotype of deficient miceStefan O Krechowec, Katie L Burton, Anna U Newlaczyl, et al.Cancer Letters|July 29, 2014
Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonismRadosław Polański, Aidan P Noon, Jeremy Blaydes, et al.Cancer Letters|March 2, 2020
TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapiesMark D Wilkie, Emad A Anaam, Andrew S Lau, et al.Cancer Research|May 3, 2008
MDM2 regulates dihydrofolate reductase activity through monoubiquitinationMaria Maguire, Paul C Nield, Timothy Devling, et al.Scientific Reports|August 6, 2020
A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populationsAli A Azar, Alison M Michie, Anuradha Tarafdar, et al.Pageof 2